If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like?
FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.
OCE’s Project 5 in 5 seeks to inspire pragmatic innovation
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Director, Oncology Center of Excellence, FDA
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents
YOU MAY BE INTERESTED IN
FDA announced recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase deficiency.
The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed.
FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.
A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
FDA has issued a draft guidance for industry that provides recommendations to sponsors about using minimal residual disease and complete response as primary endpoints in trials evaluating drugs and biologics intended to treat patients with multiple myeloma to support approval under the accelerated approval regulations.
